GLP-1 Agonists in Neurodegeneration
Reading Time: 4 minutes
Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes by helping regulate blood sugar levels and offering protective cardiovascular and renal benefits. Intriguingly, they may also …
Read MoreBarriers in Parkinson’s Disease
Reading Time: 3 minutes
Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder that targets dopamine-producing neurons in the brain’s substantia nigra and basal ganglia, leading to a spectrum of motor and nonmotor symptoms. A growing …
Read MoreBig Data in Parkinson’s Care
Reading Time: 4 minutes
Introduction
The advent of Big Data in healthcare has opened new possibilities for enhancing clinical practices, especially in managing complex diseases like Parkinson’s disease (PD). This literature review explores the existing …
Read MoreComparative Evaluation of the Hoehn and Yahr Scale and the Unified Parkinson’s Disease Rating Scale in Recent Clinical Research for Parkinson’s Disease
Reading Time: 5 minutes
Abstract
Accurately assessing Parkinson’s disease (PD) progression is crucial in clinical trials to monitor disease severity and evaluate therapeutic efficacy. In the past five years, new insights have emerged into the …
Read MoreAI-Based Parkinson’s Severity Assessment
Reading Time: 3 minutes
IntroductionParkinson’s disease (PD) is a complex neurodegenerative disorder, characterized by both motor and non-motor symptoms. Traditional methods for assessing PD severity often struggle with accuracy, especially in older patients. These …